Abstract:Background: Breast cancer incidence and mortality exhibit a rising trend globally among both premenopausal and postmenopausal women, suggesting that there are serious errors in our preventive and therapeutic measures. Purpose: Providing a series of valuable, but misunderstood inventions highlighting the role of increasing estrogen signaling in prevention and therapy of breast cancer instead of its inhibition. Results: 1. Breast cells and breast cancer cells with germline BRCA1/2 mutations similarly show defects in liganded estrogen receptor (ER) signaling, demonstrating its role in genomic instability and cancer initiation. 2. In breast tumors, the increased expression of special receptor family maybe an effort for self-directed improvement of genomic defects, while the weakness or loss of receptors indicates a defect requiring medical repair. 3. ER overexpression in breast cancer cells is capable of strengthening estrogen signaling and DNA repair, while in ER negative tumors, HER2 overexpression tries to upregulate unliganded ER activation and genome stabilization. 4. ER-positive breast cancers responsive to endocrine therapy may show a compensatory ER overexpression resulting in a transient tumor response. Breast cancers non-responsive to antiestrogen treatment exhibit HER2-overexpression for compensating the complete inhibition of hormonal ER activation. 5. In breast tumors, somatic mutations serve upregulation of ER activation via liganded or unliganded pathway helping genome stabilization and apoptotic death. 6. The mutual communication between breast cancer and its inflammatory environment is a wonderful partnership among cells fighting for genome stabilization and apoptotic death of tumor. 7. In breast cancers, there is no resistance to genotoxic or immune blocker therapies, but rather, the nonresponsive tumor cells exhaust all compensatory possibilities against therapeutic damages. Conclusions: Understanding the behavior and ambition of breast cancer cells may achieve a turn in therapy via applying supportive care instead of genotoxic measures.

Estrogen/ER in anti-tumor immunity regulation to tumor cell and tumor microenvironment

Estrogen receptor regulation of the Immune Microenvironment in Breast Cancer

Mechanisms for estrogen receptor expression in human cancer

Advances in immune regulation of the G protein-coupled estrogen receptor

Role of estrogen in hepatocellular carcinoma: is inflammation the key?

The immunomodulatory effects of endocrine therapy in breast cancer

Estrogen and Its Receptors in Cancer

Regulation of Stromal Cells by Sex Steroid Hormones in the Breast Cancer Microenvironment

Estrogen and Cancer

Estrogen Regulated Genes Compel Apoptosis in Breast Cancer Cells, Whilst Stimulate Antitumor Activity in Peritumoral Immune Cells in a Janus-Faced Manner

The Estrogen–Autophagy Axis: Insights into Cytoprotection and Therapeutic Potential in Cancer and Infection

[Molecular Mechanisms of Regulation of Estrogen Receptor a Expression Level in Breast Cancer].

The Gerogress in the Study of the Immune Regnlatory Role of Estrogen and Progesterone

The therapeutic target of estrogen receptor-alpha36 in estrogen-dependent tumors

The effects of estrogen on targeted cancer therapy drugs

Estrogen receptors participate in carcinogenesis signaling pathways by directly regulating NOD-like receptors.

Research advances in the estrogen receptors in estrogen non-target organ tumors

Selective estrogen receptor modulators contribute to prostate cancer treatment by regulating the tumor immune microenvironment

Estrogens increase cancer cell efferocytosis to establish an immunosuppressive tumor microenvironment

Clinical Relevance of Estrogen Reactivity in the Breast Cancer Microenvironment

Pharmacological Activation of Estrogen Receptor Beta Augments Innate Immunity to Suppress Cancer Metastasis